BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 16636810)

  • 21. PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination.
    Satchi-Fainaro R; Hailu H; Davies JW; Summerford C; Duncan R
    Bioconjug Chem; 2003; 14(4):797-804. PubMed ID: 12862433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymer nitric oxide donors potentiate the treatment of experimental solid tumours by increasing drug accumulation in the tumour tissue.
    Studenovsky M; Sivak L; Sedlacek O; Konefal R; Horkova V; Etrych T; Kovar M; Rihova B; Sirova M
    J Control Release; 2018 Jan; 269():214-224. PubMed ID: 29154977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymeric drug-carriers containing doxorubicin and melanocyte-stimulating hormone: in vitro and in vivo evaluation against murine melanoma.
    O'Hare KB; Duncan R; Strohalm J; Ulbrich K; Kopeckova P
    J Drug Target; 1993; 1(3):217-29. PubMed ID: 8069563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic effect of EMF-BEMER-type pulsed weak electromagnetic field and HPMA-bound doxorubicin on mouse EL4 T-cell lymphoma.
    Říhová B; Etrych T; Šírová M; Tomala J; Ulbrich K; Kovář M
    J Drug Target; 2011 Dec; 19(10):890-9. PubMed ID: 21981636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymeric drugs based on conjugates of synthetic and natural macromolecules. II. Anti-cancer activity of antibody or (Fab')(2)-targeted conjugates and combined therapy with immunomodulators.
    Ríhová B; Jelínková M; Strohalm J; Subr V; Plocová D; Hovorka O; Novák M; Plundrová D; Germano Y; Ulbrich K
    J Control Release; 2000 Feb; 64(1-3):241-61. PubMed ID: 10640661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel star HPMA-based polymer conjugates for passive targeting to solid tumors.
    Etrych T; Strohalm J; Chytil P; Říhová B; Ulbrich K
    J Drug Target; 2011 Dec; 19(10):874-89. PubMed ID: 21978286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data.
    Ríhová B; Strohalm J; Prausová J; Kubácková K; Jelínková M; Rozprimová L; Sírová M; Plocová D; Etrych T; Subr V; Mrkvan T; Kovár M; Ulbrich K
    J Control Release; 2003 Aug; 91(1-2):1-16. PubMed ID: 12932633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical experience with anthracycline antibiotics-HPMA copolymer-human immunoglobulin conjugates.
    Rihova B
    Adv Drug Deliv Rev; 2009 Nov; 61(13):1149-58. PubMed ID: 19682512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences.
    Ríhová B; Strohalm J; Hovorka O; Subr V; Etrych T; Chytil P; Pola R; Plocová D; Boucek J; Ulbrich K
    J Control Release; 2008 Apr; 127(2):110-20. PubMed ID: 18325618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
    Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
    Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of primary and metastatic tumors in mice by E-selectin-targeted polymer-drug conjugates.
    Shamay Y; Raviv L; Golan M; Voronov E; Apte RN; David A
    J Control Release; 2015 Nov; 217():102-12. PubMed ID: 26297207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biological evaluation of a novel doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells.
    Ai S; Duan J; Liu X; Bock S; Tian Y; Huang Z
    Mol Pharm; 2011 Apr; 8(2):375-86. PubMed ID: 21241067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells.
    David A; Kopecková P; Minko T; Rubinstein A; Kopecek J
    Eur J Cancer; 2004 Jan; 40(1):148-57. PubMed ID: 14687799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
    Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor activity of N-(2-hydroxypropyl) methacrylamide copolymer-Mesochlorine e6 and adriamycin conjugates in combination treatments.
    Shiah JG; Sun Y; Peterson CM; Straight RC; Kopecek J
    Clin Cancer Res; 2000 Mar; 6(3):1008-15. PubMed ID: 10741728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.
    Ganapathi R; Grabowski D; Sweatman TW; Seshadri R; Israel M
    Br J Cancer; 1989 Dec; 60(6):819-26. PubMed ID: 2605093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis of long-circulating, backbone degradable HPMA copolymer-doxorubicin conjugates and evaluation of molecular-weight-dependent antitumor efficacy.
    Pan H; Sima M; Yang J; Kopeček J
    Macromol Biosci; 2013 Feb; 13(2):155-60. PubMed ID: 23339052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic action of doxorubicin bound to the polymeric carrier based on N-(2-hydroxypropyl)methacrylamide copolymers through an amide or hydrazone bond.
    Ríhová B; Etrych T; Sírová M; Kovár L; Hovorka O; Kovár M; Benda A; Ulbrich K
    Mol Pharm; 2010 Aug; 7(4):1027-40. PubMed ID: 20524698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8
    Yin W; Song Y; Liu Q; Wu Y; He R
    Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs.
    Ríhová B; Strohalm J; Kubácková K; Jelínková M; Hovorka O; Kovár M; Plocová D; Sírová M; St'astný M; Rozprimová L; Ulbrich K
    J Control Release; 2002 Jan; 78(1-3):97-114. PubMed ID: 11772452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.